Ben Busby!

I work for NVIDIA and help out at CMU, JHU and Stanford in an effort to make Bioinformatics Better. Everything I post is my personal opinion. You're awesome!

[Ben Busby! @DCGenomics]

I like this so much!

[DNAnexus, Inc. @dnanexus]

We’re excited to connect with leaders next week at the Multi-Omics Technology Trade Gateway Event. Schedule time to connect with us to learn how our platform turns multiomics data into an evidence engine for AI-driven scientific breakthroughs: https://t.co/egXRJqtB77

[Bicycle Therapeutics @Bicycle_tx]

Last night, Jennifer Perry joined esteemed clinical and industry experts at the Women Leaders in Oncology and Allies Event, hosted in collaboration with @ConquerCancerFd.

We're proud of JP and grateful for her work helping elevate women across our field.

[Pradeep Natarajan @pnatarajanmd]

Our study led by @Yunfeng_Ruan describes a method of interpolated polygenic risk scoring (DiscoDivas) for more accurate scoring across ancestries, particularly in settings of admixture https://t.co/oE6OwDp5Ey @AJHGNews
@AniruddhPatelMD @skoyamamd @buutrg @somijemmacho @HornsbyWhitney @AndrewHaoyu @nilanjan10c

[Nextflow @nextflowio]

Become a Nextflow Ambassador in 2026!🌍

The ambassador program recognizes dedicated volunteers who contribute their time and expertise to foster collaboration & knowledge sharing across the Nextflow community.

Applications close June 14. Apply now: https://t.co/moMLj1JJRJ

[Pradeep Natarajan @pnatarajanmd]

I'm very excited to share that I will be joining @Amgen, overseeing cardiometabolic research and human genetics, starting Aug 3!

I am excited to shape target identification, biology, and drug discovery as the therapeutic area head for cardiovascular disease, obesity, and general medicine. And I will lead the human genetics efforts, spanning Amgen deCODE genetics (a subsidiary of Amgen), that drive target discovery and biology across all therapeutic areas.

I have been incredibly fortunate to interface with truly remarkable individuals and culture across @MassGenBrigham, @broadinstitute, and @harvardmed, where I could not have asked for a more meaningful and enjoyable academic career.

Being able to build on my prior work, discover and clarify therapeutic hypotheses, and now carry them through to medicines that reach millions is an opportunity I'm grateful for. I'm very excited for what comes next.

[Ming "Tommy" Tang @tangming2005]

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors https://t.co/iX4GCUF6oM

[Andrew Carroll @acarroll_ATG]

This blog shares some thoughts on protein and genome foundation models. The first part explains some of the concepts by training models for example tasks. The second part is opinion on the state of the field.

https://t.co/ZBFyFaTGdS

[DNAnexus, Inc. @dnanexus]

Join us this week at #ASCO26 to learn how our solutions provide an evidence engine for AI-driven oncology breakthroughs!

Setup time to meet with us and see how our recently announced solutions are powering the next era of precision health: https://t.co/uMwKlLc1tY

[Fabian Theis @fabian_theis]

Excited to be at the 90th Cold Spring Harbor Symposium on AI in Biology 🧬🤖

Amazing speakers & discussions amongst others on how AI moves from analyzing biology to actively helping shape next experiments. 🚀

Will talk about closing the loop in single-cell perturbation bio. 🧫

[antisense. @razoralign]

Transcriptome graph transformer: a graph transformer-based unsupervised model for transcriptome data analysis https://t.co/tZzkpyliKy

[Jian Ma @jmuiuc]

The editors at Cell Systems asked: "How is agentic AI changing how we do science?" My response- it is exciting and already happening. But progress will depend on making agentic processes more trustworthy and accountable. The full Voices piece includes perspectives from several colleagues in the field. https://t.co/jNcL4rMNlv

[Bo Wang @BoWang87]

My student Phil just co-founded Blank Bio through @ycombinator , and they just raised a $7.2M seed round with a strategic collaboration with @PacBio

@blankbio_ is building RNA foundation models for precision oncology, inspired by Orthrus (https://t.co/5IPpDoeJRm), our Nature Methods work showing that RNA models become much more powerful when trained with biological structure: splicing, evolution, and function.

Clinical trials still rely on crude proxies of tumor biology to make billion-dollar decisions.

RNA contains a much richer signal: disease state, regulation, progression, and treatment response.

Excited to see Phil and the Blank Bio team translate biologically grounded foundation models into better trial design: smaller, smarter, and more likely to bring effective therapies to patients.

[Peter Koo @pkoo562]

[SAVE THE DATE] MLCB 2026 will be held Nov 16–17 at the New York Genome Center in NYC!

Submission deadline is July 1 AOE
• 8-page full papers: oral or poster, with optional proceedings
• 2-page work-in-progress papers: posters

Spread the word! RT!

https://t.co/BTmQMzLN4d

[Jose V. Die @jdieramon]

La mutación es un proceso natural . La tasa de mutación se puede estimar . El análisis de todas las secuencias disponibles hasta la fecha del brote actual no confirman lo que queréis sugerir . Por tanto , vuestro titular es engañoso y contribuye a generar confusión .

[Steven Salzberg 💙💛 @StevenSalzberg1]

two weeks after his death, Craig Venter is a co-author on one more paper, this one a preprint describing an improved assembly of his own genome https://t.co/aY40lhoRJr

[antisense. @razoralign]

scArchon: a scalable benchmarking framework for assessing single-cell perturbation models https://t.co/Mil7WVjQ0m

[Ken Wang @Weixu_Ken_Wang]

Thrilled to share that my work RegVelo is out in Cell! 🎉
RegVelo integrates structural equation models into splicing dynamics so perturbation outputs directly link to cell fate decisions.
Deeply grateful to my mentors, also actively looking for positions in AI4bio, open to chat!

[Katherine Aird @airdlab]

Our lab is expanding and hiring both a postdoc and staff scientist! We study how metabolism and cell cycle states drive tumor progression, therapy response, and immune interactions. Philly is a great place to live and do research! See more at: https://t.co/Qptg5QHh66.

[Joe Pickrell @joe_pickrell]

Interesting that the most common recessive disorder (alpha-thalessemia) in the UAE can't be reliably screened via standard short read sequencing.

From "Citywide premarital genomic screening in a Middle Eastern population"

https://t.co/8gdByd2VIc

[Karsten Suhre @ksuhre]

Meta-analysis across six global biobanks identifies recessive coding associations with complex traits and diseases: The American Journal of Human Genetics https://t.co/5NDwcxqdAG